Description of Business - Additional Information (Detail)				12 Months Ended
	Dec. 11, 2024 USD ($) shares	Oct. 18, 2024 $ / shares shares	Jul. 03, 2024 USD ($) shares	Dec. 31, 2024 $ / shares shares	Dec. 31, 2023 shares
Common stock, par value | $ / shares				$ 0.001
Common stock, shares issued | shares				42,323,759	12,167,679
Common stock, shares authorized | shares				75,000,000
Kintara Therapeutics Inc [Member]
Reverse stock split, description		1-for-35
Reverse stock split		35
Common stock, par value | $ / shares		$ 0.001
Common stock, shares issued | shares		40,441,605		40,441,605
Common stock exchange ratio		0.1789		0.1789
Contingent value rights entitled to receive common stock, shares | shares		1,539,918
Merger agreement, cash consideration | $	$ 9,005,000
Total merger consideration | $	15,000,000
Mergder consideration, advance amount | $	$ 5,995,000
Share component of merger consideration | shares	3,476,568
Holdback of shares | shares	869,142
Clinical trial expenses | $	$ 900,000
Working capital loan | $	2,000,000
Contingent working capital loan | $	1,750,000
Working capital deficit | $	$ 12,000,000
Common stock, shares authorized | shares	200,000,000
July Two Thousand And Twenty Four Private Placement [Member]
Proceeds from private placement | $			$ 5,000,000
Issuance of shares, shares | shares			717,321
Royalty as a percentage of sales			1.50%